Roopom Banerjee

Seminars

Thursday 25th September 2025
Ultra-sensitive PathlightTM MRD Detects Recurrence Sooner, Enabling Therapeutic Intervention Earlier
11:50 am
  • PathlightTM MRD's novel approach tracking structural variants has enabled best in class performance in early Breast Cancer
  • Commercial launch and positive MolDx coverage decision of PathlightTM in early breast cancer have expanded access for clinicians and patients
  • SAGA is enabling pharma access to this test to drive earlier therapeutic intervention for novel therapeutics in early breast cancer
View all Speakers
View Event Brochure